1. Home
  2. NGNE vs NECB Comparison

NGNE vs NECB Comparison

Compare NGNE & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • NECB
  • Stock Information
  • Founded
  • NGNE 2003
  • NECB 1934
  • Country
  • NGNE United States
  • NECB United States
  • Employees
  • NGNE N/A
  • NECB N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • NECB Savings Institutions
  • Sector
  • NGNE Health Care
  • NECB Finance
  • Exchange
  • NGNE Nasdaq
  • NECB Nasdaq
  • Market Cap
  • NGNE 251.9M
  • NECB 281.2M
  • IPO Year
  • NGNE N/A
  • NECB N/A
  • Fundamental
  • Price
  • NGNE $15.42
  • NECB $23.44
  • Analyst Decision
  • NGNE Strong Buy
  • NECB
  • Analyst Count
  • NGNE 7
  • NECB 0
  • Target Price
  • NGNE $41.86
  • NECB N/A
  • AVG Volume (30 Days)
  • NGNE 193.9K
  • NECB 30.5K
  • Earning Date
  • NGNE 08-08-2025
  • NECB 07-21-2025
  • Dividend Yield
  • NGNE N/A
  • NECB 3.42%
  • EPS Growth
  • NGNE N/A
  • NECB 0.72
  • EPS
  • NGNE N/A
  • NECB 3.44
  • Revenue
  • NGNE $925,000.00
  • NECB $104,392,000.00
  • Revenue This Year
  • NGNE N/A
  • NECB $2.80
  • Revenue Next Year
  • NGNE N/A
  • NECB $8.34
  • P/E Ratio
  • NGNE N/A
  • NECB $6.81
  • Revenue Growth
  • NGNE N/A
  • NECB 2.77
  • 52 Week Low
  • NGNE $6.88
  • NECB $17.11
  • 52 Week High
  • NGNE $74.49
  • NECB $31.72
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 40.98
  • NECB 57.21
  • Support Level
  • NGNE $19.13
  • NECB $22.34
  • Resistance Level
  • NGNE $18.21
  • NECB $23.73
  • Average True Range (ATR)
  • NGNE 1.59
  • NECB 0.61
  • MACD
  • NGNE -0.59
  • NECB 0.11
  • Stochastic Oscillator
  • NGNE 4.26
  • NECB 80.73

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NECB NorthEast Community Bancorp Inc.

NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.

Share on Social Networks: